Literature DB >> 26422444

The role of Smad3 in the fibrotic phenotype in human vocal fold fibroblasts.

Ryan C Branski, Renjie Bing, Iv Kraja, Milan R Amin1.   

Abstract

OBJECTIVES/HYPOTHESIS: To investigate the role of Smad3 as a regulator of transforming growth factor (TGF)-β1-mediated cell activities associated with fibrosis in normal human vocal fold fibroblasts. We also sought to confirm the temporal stability of Smad3 knockdown via small inhibitor ribonucleic acid (siRNA). Vocal fold fibroblasts were employed to determine the effects of Smad3 knockdown on TGF-β1-mediated migration and contraction, as well as regulation of connective tissue growth factor (CTGF). We hypothesized that Smad3 is an ideal candidate for therapeutic manipulation in vivo based on its role in fibrosis. STUDY
DESIGN: In vitro.
METHODS: Knockdown of Smad3 via siRNA was performed in our normal human vocal fold cell line. Three-dimensional collagen gel contraction and scratch assays were employed to determine the role of Smad3 on TGF-β1-mediated contraction and migration, respectively. The role Smad3 in the induction of CTGF was characterized via sodium dodecyl sulfate polyacrylamide gel electrophoresis. The effects of Smad3 signaling on Smad7 messenger (m)RNA and protein were also quantified.
RESULTS: Smad3 knockdown was temporally-stable up to 72 hours (P < 0.001), diminished TGF-β1-mediated collagen gel contraction and migration, and blunted induction of CTGF, but it had no effect on TGF-β1-mediated Smad7 mRNA or protein induction.
CONCLUSION: Transforming growth factor-β1 stimulated profibrotic cell activities in our cell line and these actions were largely reduced with Smad3 knockdown. These data provide continued support for therapeutic targeting of Smad3 for vocal fold fibrosis because it appears to regulate the fibrotic phenotype. LEVEL OF EVIDENCE: N/A. Laryngoscope, 126:1151-1156, 2016.
© 2015 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Smad3; TGF-β; Voice; fibrosis; scar; vocal fold

Mesh:

Substances:

Year:  2015        PMID: 26422444      PMCID: PMC4814357          DOI: 10.1002/lary.25673

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  24 in total

Review 1.  RNA-based therapeutics: current progress and future prospects.

Authors:  John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2012-01-27

2.  Immediate inflammatory response and scar formation in wounded vocal folds.

Authors:  Xinhong Lim; Ichiro Tateya; Tomoko Tateya; Alejandro Muñoz-Del-Río; Diane M Bless
Journal:  Ann Otol Rhinol Laryngol       Date:  2006-12       Impact factor: 1.547

3.  Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis.

Authors:  Vlad C Sandulache; Aron Parekh; HaSheng Li-Korotky; Joseph E Dohar; Patricia A Hebda
Journal:  Wound Repair Regen       Date:  2007 Jan-Feb       Impact factor: 3.617

4.  Prostaglandin (PG)E2 exhibits antifibrotic activity in vocal fold fibroblasts.

Authors:  Hang Zhou; Diane Felsen; Vlad C Sandulache; Milan R Amin; Dennis H Kraus; Ryan C Branski
Journal:  Laryngoscope       Date:  2011-05-06       Impact factor: 3.325

5.  Subglottic stenosis examined as a fibrotic response to airway injury characterized by altered mucosal fibroblast activity.

Authors:  Tripti Singh; Vlad C Sandulache; Todd D Otteson; Mark Barsic; Edwin C Klein; Joseph E Dohar; Patricia A Hebda
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-02

6.  Prostaglandin E2 is activated by airway injury and regulates fibroblast cytoskeletal dynamics.

Authors:  Vlad C Sandulache; Tripti Singh; Ha Sheng Li-Korotky; Chia Y Lo; Todd D Otteson; Mark Barsic; Joseph E Dohar; Patricia A Hebda
Journal:  Laryngoscope       Date:  2009-07       Impact factor: 3.325

7.  Effects of transforming growth factor-beta1 on human vocal fold fibroblasts.

Authors:  Ryan C Branski; Silvia S Barbieri; Babette B Weksler; Benjamin Saltman; Priya Krishna; Dennis H Kraus; Nalini V Broadbelt; Jie Chen; Dix P Poppas; Diane Felsen
Journal:  Ann Otol Rhinol Laryngol       Date:  2009-03       Impact factor: 1.547

8.  Smad3: an emerging target for vocal fold fibrosis.

Authors:  Benjamin C Paul; Benjamin Y Rafii; Sonate Gandonu; Renjie Bing; Hayley Born; Milan R Amin; Ryan C Branski
Journal:  Laryngoscope       Date:  2014-05-27       Impact factor: 3.325

9.  Prostaglandin E2 differentially regulates contraction and structural reorganization of anchored collagen gels by human adult and fetal dermal fibroblasts.

Authors:  Aron Parekh; Vlad C Sandulache; Tripti Singh; Selma Cetin; Michael S Sacks; Joseph E Dohar; Patricia A Hebda
Journal:  Wound Repair Regen       Date:  2009 Jan-Feb       Impact factor: 3.617

Review 10.  Knocking down barriers: advances in siRNA delivery.

Authors:  Kathryn A Whitehead; Robert Langer; Daniel G Anderson
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

View more
  10 in total

1.  Porcine Vocal Fold Lamina Propria-Derived Biomaterials Modulate TGF-β1-Mediated Fibroblast Activation in Vitro.

Authors:  Camilo Mora-Navarro; Andreea Badileanu; Ana M Gracioso Martins; Emily W Ozpinar; Lewis Gaffney; Ian Huntress; Erin Harrell; Jeffrey R Enders; Xinxia Peng; Ryan C Branski; Donald O Freytes
Journal:  ACS Biomater Sci Eng       Date:  2020-02-11

2.  Nanoparticle delivery of RNA-based therapeutics to alter the vocal fold tissue response to injury.

Authors:  Nao Hiwatashi; Iv Kraja; Peter A Benedict; Gregory R Dion; Renjie Bing; Bernard Rousseau; Milan R Amin; Danielle M Nalband; Kent Kirshenbaum; Ryan C Branski
Journal:  Laryngoscope       Date:  2017-12-14       Impact factor: 3.325

3.  Phosphorylation of the glucocorticoid receptor alters SMAD signaling in vocal fold fibroblasts.

Authors:  Shigeyuki Mukudai; Nao Hiwatashi; Renjie Bing; Michael Garabedian; Ryan C Branski
Journal:  Laryngoscope       Date:  2018-10-16       Impact factor: 3.325

4.  The effects of cytosporone-B, a novel antifibrotic agent, on vocal fold fibroblasts.

Authors:  Nao Hiwatashi; Shigeyuki Mukudai; Renjie Bing; Ryan C Branski
Journal:  Laryngoscope       Date:  2018-10-16       Impact factor: 3.325

5.  NR4A1 is an endogenous inhibitor of vocal fold fibrosis.

Authors:  Nao Hiwatashi; Renjie Bing; Iv Kraja; Ryan C Branski
Journal:  Laryngoscope       Date:  2017-06-05       Impact factor: 3.325

6.  Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts.

Authors:  Iv Kraja; Renjie Bing; Nao Hiwatashi; Bernard Rousseau; Danielle Nalband; Kent Kirshenbaum; Ryan C Branski
Journal:  Laryngoscope       Date:  2016-12-20       Impact factor: 3.325

7.  SMAD3 expression and regulation of fibroplasia in vocal fold injury.

Authors:  Nao Hiwatashi; Peter A Benedict; Gregory R Dion; Renjie Bing; Iv Kraja; Milan R Amin; Ryan C Branski
Journal:  Laryngoscope       Date:  2017-05-20       Impact factor: 3.325

8.  Antifibrotic effects of eupatilin on TGF-β1-treated human vocal fold fibroblasts.

Authors:  Sung Joon Park; Hyunsu Choi; Ji Heon Kim; Choung-Soo Kim
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

9.  Concurrent YAP/TAZ and SMAD signaling mediate vocal fold fibrosis.

Authors:  Ryosuke Nakamura; Nao Hiwatashi; Renjie Bing; Carina P Doyle; Ryan C Branski
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

10.  Implementing Efficient Peptoid-Mediated Delivery of RNA-Based Therapeutics to the Vocal Folds.

Authors:  Shigeyuki Mukudai; Iv Kraja; Renjie Bing; Danielle M Nalband; Mallika Tatikola; Nao Hiwatashi; Kent Kirshenbaum; Ryan C Branski
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-10-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.